 SELLAS Life Sciences Group Inc. NASDAQ: SLS shares were trading lower Wednesday after the company released updated clinical and initial immunobiological data from a Phase 12 clinical trial ofits lead asset, galinpepimut-S, the companys Wilms Tumor-1-targeting peptide immunotherapeutic, in combination with the checkpoint inhibitor Keytruda. Sellas Life Sciences was down 15.76 at 11.01 at last check Wednesday. 